Dateline City:
KENILWORTH, N.J.
Response Rates from KEYNOTE-055 Show Nearly One in Five Patients Responding with KEYTRUDA; Results Confirm Findings from KEYNOTE-012
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced new data with KEYTRUDA (pembrolizumab), the
companys anti-PD-1 therapy, as a monotherapy from two studies
(KEYNOTE-012 and KEYNOTE-055) in heavily pre-treated patients with
recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Data are being presented at the 52nd Annual Meeting of the
American Society of Clinical Oncology (ASCO) in Chicago.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558An Phan, 908-255-6325orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more